NCT00970047已完成不适用
Development of a Noninvasive Fetal Sex Determination Test Between 6 and 16 Weeks of Gestation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 500
- 试验地点
- 3
研究概览
简要总结
Whole blood from pregnant women will be collected to develop a noninvasive fetal sex test.
详细描述
This is an observational study whereby samples will be tested to determine the presence or absence of fetal Y chromosome genes to test for the fetal sex of the baby. The blood draw will occur between 6 to 16 weeks of gestation. The fetal gender will be requested at or soon after delivery if fetal sex was not previously obtained by CVS or amniocentesis genetic analysis.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 64 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subject is 18-64 years of age
- •Subject is female
- •Subject is pregnant and between 6 and 16 weeks of gestation
- •Subject provides a signed and dated informed consent
- •If subject undergoes a routine ultrasound between weeks 16 and 28, she agrees to provide the fetal sex results
- •If subject undergoes an invasive procedure, she agrees to provide the fetal sex results
排除标准
- 未提供
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal BloodTrisomy 21Trisomy 18Sex Chromosome AbnormalitiesMicrodeletion SyndromesTrisomy 13NCT01852708Natera, Inc.1,059
终止
不适用
Development of a NIPTT for Detecting Copy Number VariationsCopy Number VariationsNCT04774640Sequenom, Inc.9
已完成
不适用
Non-invasive Prenatal Diagnostic Validation StudyChromosome 13 AneuploidyChromosome 18 AneuploidyChromosome 21 AneuploidySex Chromosome AberrationsOther MicrodeletionsNCT01574781Natera, Inc.1,781
招募中
不适用
Specimen Collection From Pregnant Women at Increased Risk for Fetal AneuploidyDown SyndromeFetal AneuploidyNCT01429389Sequenom, Inc.2,000
已完成
不适用
Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved PregnanciesFetal Sex DeterminationNCT01021085Sequenom, Inc.500
